Early management of acute severe UC in the biologics era: development and international validation of a prognostic clinical index to predict steroid response.
Journal article
Adams A. et al, (2022), Gut
Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.
Journal article
Selim R. et al, (2022), Lancet Gastroenterol Hepatol
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
Journal article
Wellens J. et al, (2022), Gut, 71, 1919 - 1922
Author Correction: Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.
Journal article
Serra EG. et al, (2022), Nat Commun, 13
Observational data from the adalimumab post‐marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis
Journal article
Hart A. et al, (2022), United European Gastroenterology Journal, 10, 485 - 495
BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
Conference paper
Wellens J. et al, (2022), GASTROENTEROLOGY, 162, S278 - S278
PERIPHERAL BLOOD DNA METHYLATION BIOMARKERS ACCURATELY PREDICT CLINICAL- AND ENDOSCOPIC RESPONSE TO VEDOLIZUMAB IN A REAL-LIFE COHORT OF CROHNS DISEASE PATIENTS
Conference paper
Joustra VW. et al, (2022), GASTROENTEROLOGY, 162, S794 - S794
TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE
Conference paper
Wong S-Y. et al, (2022), GASTROENTEROLOGY, 162, S1004 - S1005
WITHDRAWAL OF INFLIXIMAB OR ANTI-METABOLITE THERAPY IN CROHN'S DISEASE PATIENTS IN SUSTAINED REMISSION ON COMBINATION THERAPY: A RANDOMIZED UNBLINDED CONTROLLED TRIAL (SPARE)
Conference paper
Louis E. et al, (2022), GASTROENTEROLOGY, 162, S216 - S216
Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease.
Journal article
Zhang S. et al, (2022), JCI Insight
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
Journal article
Wellens J. et al, (2022), Lancet Gastroenterol Hepatol
Probing the Microbiome to Predict Response to Biologic Therapy in Inflammatory Bowel Disease-One Step Closer to Precision Medicine?
Journal article
Revés J. et al, (2022), Gastroenterology
Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2
Journal article
Nowak JK. et al, (2022), Journal of Crohn's and Colitis
Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort.
Journal article
Vatn SS. et al, (2022), Clin Exp Gastroenterol, 15, 5 - 25
Systemic Inflammation in Preclinical Ulcerative Colitis.
Journal article
Bergemalm D. et al, (2021), Gastroenterology, 161, 1526 - 1539.e9
SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
Journal article
Selim R. et al, (2021), Lancet Gastroenterol Hepatol
Anti-TNFα vs thiopurines for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis of individual participant data
Journal article
Beelen EMJ. et al, (2021), Clinical Gastroenterology and Hepatology
Anti-SARS-CoV-2 antibody responses in patients with IBD treated with biologics - are we finding CLARITY?
Journal article
Chapman TP. et al, (2021), Gastroenterology
Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021.
Journal article
Gupta V. et al, (2021), J Crohns Colitis, 15, 1211 - 1221